Trials
Search / Trial NCT05639946

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Launched by UNIVERSITY OF MINNESOTA · Dec 5, 2022

Trial Information

Current as of January 14, 2025

Active, not recruiting

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years of age or older
  • Injured for \> 3 months
  • Completed inpatient rehabilitation and living in the community
  • Chronic sublesional neuropathic pain defined as persistent pain (VAS grade 3-10) for three months or more
  • For people of child-bearing potential: currently practicing an effective form of two types of birth control (defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly).
  • Exclusion Criteria:
  • Progressive myelopathy secondary to posttraumatic cord tethering or syringomyelia
  • Active use of drugs known to interact with brivaracetam: rifampin, carbamazepine, sodium oxybate, buprenorphine, propoxyphene, levetiracetam, and phenytoin.
  • Brain injury or cognitive impairment limiting the ability to follow directions or provide informed consent
  • Pregnancy or lactation
  • Epilepsy or active treatment for seizure disorder
  • Past or current suicidality
  • Active treatment for psychiatric disease
  • Drug addiction
  • Moderate or heavy alcohol intake (up to four alcoholic drinks for men and three for women in any single day, and a maximum of 14 drinks for men and 7 drinks for women per week)
  • Hepatic cirrhosis, Child-Pugh grades A, B, and C
  • Impaired renal function (GFR\<60ml/minute)
  • Contraindications to brivaracetam or pyrrolidine derivatives including allergy
  • Active clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular, pulmonary, endocrine, psychiatric, hematologic, urologic, or other acute or chronic illness) that, in the opinion of the investigator, would make the patient an unsuitable candidate for this trial.
  • History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of brivaracetam
  • Use of any investigational drug 30 days prior to enrollment in this study
  • Enrollment in another clinical trial.

Trial Officials

Ricardo Battaglino, PhD

Principal Investigator

University of Minnesota

About University Of Minnesota

The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.

Locations

Minneapolis, Minnesota, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials